2010
DOI: 10.1007/s00284-010-9682-6
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of the Antiviral Activity for Influenza Viruses M1 Zinc Finger Peptides

Abstract: We sought to investigate the cellular uptake and antiviral activity for the M1 zinc finger peptides derived from influenza A and influenza B viruses in vitro. No cellular uptake was detected by fluorescent microscopy for the synthetic zinc finger peptides. When flanked to a cell permeable peptide Tp10, the zinc finger recombinant proteins were efficiently internalized by MDCK cells. However, no antiviral activity was detected against homologous or heterologous virus infections for the synthetic peptides or the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2011
2011
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 22 publications
0
2
0
Order By: Relevance
“…Zn fingers bind RNA and mediate protein-protein interactions. A Zn finger protein was found to inhibit influenza virus replication [35][36][37][38]. Under experimental conditions, Zn combines with TMP forming fixed complex preserving the anti-bacterial properties of TMP but without evidence of anti-virus [39,40].…”
Section: Discussionmentioning
confidence: 99%
“…Zn fingers bind RNA and mediate protein-protein interactions. A Zn finger protein was found to inhibit influenza virus replication [35][36][37][38]. Under experimental conditions, Zn combines with TMP forming fixed complex preserving the anti-bacterial properties of TMP but without evidence of anti-virus [39,40].…”
Section: Discussionmentioning
confidence: 99%
“…Peptides mimicking influenza virus RdRp binding sites also showed anti-influenza activity [4143]. However, the results for the zinc finger motif peptide of M1 being used for the inhibition of influenza virus are controversial [4446]. Zanamivir was developed from the non-inhibitory prototype sialidase inhibitor [47,48].…”
Section: Discussionmentioning
confidence: 99%